An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Jan 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2020.
- 02 Oct 2017 Status changed from not yet recruiting to recruiting.
- 02 Oct 2017 Planned End Date changed from 1 Mar 2021 to 1 Sep 2021.